A5057431823- Endometrial and Cervical Cancer Treatments
- Endometriosis Research and Treatment
- Ovarian cancer diagnosis and treatment
- Cancer Risks and Factors
- Cervical Cancer and HPV Research
- Cancer Immunotherapy and Biomarkers
- Uterine Myomas and Treatments
- Genetic factors in colorectal cancer
- Estrogen and related hormone effects
- Medical and Agricultural Research Studies
- Reproductive System and Pregnancy
- Multiple and Secondary Primary Cancers
- Breast Cancer Treatment Studies
- BRCA gene mutations in cancer
- Advanced Breast Cancer Therapies
- Gestational Trophoblastic Disease Studies
- Renal cell carcinoma treatment
- Cancer, Stress, Anesthesia, and Immune Response
- Nutrition, Genetics, and Disease
- Bladder and Urothelial Cancer Treatments
- Maternal and fetal healthcare
- Pancreatic and Hepatic Oncology Research
- Ectopic Pregnancy Diagnosis and Management
- COVID-19 Impact on Reproduction
- Metastasis and carcinoma case studies
St Petersburg University
2014-2024
Ministry of Health of the Russian Federation
2017-2024
Federal Almazov North-West Medical Research Centre
2017-2024
North-Western State Medical University named after I.I. Mechnikov
2013-2022
Research Institute of Obstetrics and Gynecology named after D.O. Ott
2022
Avaya (Bermuda)
2021
Aim . To assess the efficacy and safety of lenvatinib pembrolizumab for treatment mismatch repair-proficient endometrial cancer (EC) in routine clinical practice Russia. Materials methods This multicenter, retrospective, cohort study included patients with recurrent metastatic EC from 37 centers Russia treated between May 2020 April 2023. Patients histologically verified without microsatellite instability who received ≥1 course pembrolizumab/lenvatinib therapy were study. The primary...
The article discusses the possibilities of cervical cancer primary and secondary prevention.It is noted that normalization folate levels in peripheral blood red cells opens up new opportunities to reduce risk human papillomavirus persistence, neoplasia development further cancer.
Currently, tamoxifen is the gold standard in treatment of hormone receptor-positive breast cancer, which reduces recurrent tumor risk by more than 40%. Tamoxifen, belongs to selective estrogen receptor modulators, can cause endometrial changes women different age groups and increase hyperplasia cancer several times. In clinical practice, occurrence various alterations during often leads groundless drug withdrawal. Oncology, gynecology radiology community knowledge related optimal methods...
Background. Endometrial cancer (EC) dominates in the structure of gynecological morbidity. There has been an increase this nosology women reproductive age. The morphological precancerous form endometrioid adenocarcinoma is endometrial intraepithelial neoplasia (EIN), or atypical hyperplasia (AEH), that difficult to diagnose: there a high percentage underdiagnosis resulting wrong treatment strategy. To improve accuracy diagnosis, additional immunohistochemical markers are being studied not...
The All-Russian Expert Concilium about the influence of combined oral contraceptives on breast tissue took place in 18 th April 2024 Moscow. It is necessary to study how manage controlled risk factors malign tumours. female widely discussed due enlargement possible estrogen components list. also actual if combines may act as potential enhancer/silencer for benign mammary dysplasia and cancer risk. present article demonstrates. Consensus statement Russian society obstetricians gynecologists...
In most cases, ovarian cancer is diagnosed at advanced stages, leading to a poor prognosis. Currently, there no effective screening for cancer, so detecting it in the early stages fairly successful case.
Background. Endometrial cancer (EC) treatment outcomes need to be improved. Immunotargeted therapy lead long-term and delayed effects compared chemotherapy. Estimation of efficacy quality life are crucial when we talking about in whole. Aim. To evaluate the clinical lenvatinib plus pembrolizumab patients with EC. Materials methods . The study included 43 stages I-IV EC mismatch repair-proficient tumors duration more than 9 months. We evaluated median progression-free survival, objective...
Цель исследования: Анализ публикаций о существующих методах сохранения фертильности у пациентов репродуктивного возраста, перед проведением гонадотоксичной противоопухолевой терапии. Материал и методы: Обзор статей, опубликованных в зарубежной отечественной литературе за последние 10 лет. Результаты: Проблема становится более актуальной с каждым годом. На сегодняшний день все чаще поднимается вопрос не только проведении наиболее эффективного лечения онкологических заболеваний, но последующем...
This article describes a clinical case of pregnancy management in patient after surgical treatment low-grade squamous intraepithelial lesions (LSIL) the cervix and endometrial cancer. In structure female oncological morbidity, precancerous conditions malignant diseases genital organs occupy leading positions require most sparing women who have not realized reproductive function. The frequency miscarriage early associated with history cancer, requiring repeated invasive manipulations to...
Aim. To assess the efficacy and safety of lenvatinib plus pembrolizumab for treatment mismatch repair-proficient (pMMR) endometrial cancer (EC) in routine clinical practice Russia. Materials methods. This multicenter, retrospective, cohort study included 114 patients with recurrent metastatic EC from 37 centers Russia treated between December 2020 November 2024. Patients histologically verified without microsatellite instability were included. The primary endpoint was progression-free...
Currently endometrial cancer remains a pressing issue for public health worldwide. Every year there is steady increase in morbidity rates, which associated with an the prevalence of risk factors disease among “non-steroid triad” prevalent: obesity, diabetes, metabolic syndrome. Other significant include long-term use tamoxifen and presence Lynch syndrome, makes it possible to carry out selective screening these groups patients. Endometrial symptomatic disease, main clinical manifestation...
Ovarian cancer mortality rates hold a leading position among women’s cancer, which is primarily associated with the pathogenetic features of ovarian heterogeneity disease, lack effective screening and diagnostic methods for early detection. The causes most tumors remain unknown. benign tumor-like formations are not risk factors cancer. purpose this literature review to highlight latest data from world expert organizations on possibilities neoplasm diagnosis treatment.
Microsatellite instability, which is caused by a deficiency in the DNA unpaired nucleotide repair system, an important pathogenetic event for some tumors. In addition, detection of this molecular feature becomes independent prognostic factor course disease and predictor appointment therapy with immune checkpoint inhibitors. Immunohistochemistry reliable available method detecting mismatch it has recommended as screening hereditary syndromes associated microsatellite instability. This article...
Background. In 2016, the World Health Organization published an updated version of Histological Classification for ovarian tumors presenting a new category endometriosis-associated tumors. The predictors malignant transformation endometriosis have not been clearly defined so far. Purpose. search histological and immunohistochemical markers malignancy. Materials methods. 28 female patients with endometrioid cancer 11 clear cell carcinoma were enrolled. studies carried out using conventional...
Use of the method liquid-based cytology with next immunocytochemical study endometrium is expedient for differential diagnosis endometrial pathology processes. The level gene PTEN and steroid receptors expression higher in cases simple hyperplasia without atypia. Increase markers p53 Ki67 was found only by atypical hyperplasia. Positive reaction on CD138 determines inflammatory process.
The article describes the review of literature risk factors for fibrocystic disease (FCD), role and place individual such as mammographic density cyclic mastalgia. evaluation significant clinical symptoms a factor breast cancer (BC) was made. modern possibilities diagnostics FCD are considered. recommendations on medical tactics given. pathogenetic treatment aimed at preventing is described; use Progestogel® drug prophylaxis.
Hypothesis/aims of study. The current analysis was undertaken to assess the incidence malignant diseases in patients with endometriosis.
 Study design, materials and methods. This is a cohort study women surgically verified endometriosis retrieved from Saint Petersburg 122 Clinical Hospital Discharge Register 1996–2006 (n = 1551). Data were linked Cancer Agency identify cases malignancy.
 Results. Malignant identified 6.3% 98) cases. median follow-up 12.2 (7.5) years. Breast cancer...